AbbVie
ABBV
$215.40
+1.16%
AbbVie is a global pharmaceutical company focused on developing and commercializing therapies across immunology, oncology, neuroscience, and aesthetics. It is a market leader in immunology with blockbuster drugs like Skyrizi and Rinvoq, and has solidified its position through strategic acquisitions, including Allergan in 2020 and Cerevel and ImmunoGen in 2024. The current investor narrative centers on the successful transition away from Humira's patent cliff, driven by the explosive growth of its immunology portfolio, while recent news highlights pipeline catalysts in obesity and Crohn's disease, regulatory developments, and navigating competitive and political pressures in the drug pricing landscape.…
ABBV
AbbVie
$215.40
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating & Thesis: Hold. AbbVie is a Hold as the successful immunology transition and strong cash flow are offset by extreme earnings volatility and a premium trailing valuation, creating a balanced risk/reward profile at the current price. This aligns with the mixed but generally steady analyst sentiment, which includes both bullish upgrades and neutral stances.
Supporting Evidence: The investment case is supported by four key data points: 1) Robust forward valuation with a P/E of 13.41x based on estimated EPS of $20.11, implying a price target near $270 and significant upside. 2) Strong revenue growth of 10.04% YoY, successfully driven by the new immunology portfolio. 3) Exceptional free cash flow generation of $18.70B TTM, supporting shareholder returns. 4) A defensive beta of 0.305, offering portfolio stability. However, these are counterbalanced by a precarious trailing P/E of 96.26x and erratic quarterly margins.
Risks & Conditions: The two biggest risks are unsustainable profit margins and intensifying competition for Skyrizi. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of stable, high-single-digit net margins (e.g., >8%) or if the stock price falls to ~$190, offering a larger margin of safety. It would downgrade to a Sell if quarterly net income consistently falls below $1 billion or if revenue growth decelerates below 5% YoY. Based on the forward multiple, the stock appears fairly valued relative to its near-term earnings potential, but it is overvalued on a trailing basis, indicating the market is paying for expected future normalization.
Sign up to view all
ABBV 12-Month Price Forecast
The outlook for AbbVie is one of cautious optimism tempered by significant near-term uncertainty. The company's fundamental story is intact—cash flow is robust and new drugs are growing—but the path of earnings is too erratic to warrant a bullish stance with high confidence. The base case of gradual appreciation toward the $255-$265 range is most probable, driven by earnings growth as margins hopefully stabilize. The stance would upgrade to bullish on evidence of two consecutive quarters of stable, improved profitability. It would turn bearish if competitive news worsens or if the next quarterly report shows a dramatic margin drop, confirming the volatility is structural rather than episodic.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $280.02 and implied upside of +30.0% versus the current price.
Average Target
$280.02
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$172 - $280
Analyst target range
Analyst coverage is robust with 15 analysts providing estimates, indicating strong institutional interest. The consensus sentiment is bullish, as evidenced by recent institutional ratings which include actions like 'Overweight' from Morgan Stanley and an upgrade to 'Buy' from HSBC, though some maintain 'Neutral' stances. The average target price is not explicitly provided in the data, but the estimated EPS average for the forward period is $20.11, which, when combined with the forward P/E of 13.41x, implies a consensus price target in the $270 range, suggesting significant upside from the current $217.72. The target range is wide, with estimated EPS spanning from a low of $19.58 to a high of $20.46; the high target likely assumes successful pipeline execution, sustained immunology growth, and margin expansion, while the low target may factor in competitive pressures, pipeline setbacks, or margin compression. The recent pattern of reiterated bullish ratings and one upgrade signals generally steady analyst confidence, though the lack of a dramatic shift suggests expectations are already elevated and baked into the current price.
Bulls vs Bears: ABBV Investment Factors
The bull case for AbbVie is anchored in its successful navigation of the Humira patent cliff, with Skyrizi and Rinvoq driving robust revenue growth and generating enormous free cash flow. The bear case focuses on the extreme volatility in quarterly profitability, which makes the sky-high trailing P/E multiple precarious, compounded by emerging competitive threats and a leveraged balance sheet. Currently, the bull side holds stronger evidence due to the concrete success of the immunology transition and the compelling forward valuation, but the single most important tension is the sustainability of profit margins. If the Q4 2025 margin spike proves unsustainable and profitability reverts to Q3 2025 levels, the forward earnings estimates underpinning the attractive valuation would be at severe risk, invalidating the core investment thesis.
Bullish
- Strong Immunology Growth Offsets Humira Cliff: Skyrizi and Rinvoq generated $7.38B in Q4 2025, driving a 10.04% YoY revenue increase to $16.62B. This demonstrates the successful transition from Humira, which has declined to $1.25B in the quarter.
- Massive Free Cash Flow Supports Capital Returns: TTM free cash flow of $18.70B supports a consistent dividend (payout ratio of 2.76) and share repurchases. This robust cash generation mitigates concerns from the leveraged balance sheet (Debt/Equity of -21.12).
- Attractive Forward Valuation: The forward P/E of 13.41x is compelling relative to the trailing P/E of 96.26x, implying a significant earnings recovery is priced in. This forward multiple suggests the stock is reasonably valued for a large-cap pharma.
- Pipeline Catalysts in High-Growth Areas: Recent news highlights promising early obesity drug data (up to 10% weight loss) and strong Phase 3 results for Skyrizi in Crohn's disease (55% remission). These represent significant long-term growth opportunities.
Bearish
- Extreme Earnings Volatility and Margin Swings: Net margin swung from 10.93% in Q4 2025 to 1.18% in Q3 2025, and gross margin spiked from 66.38% to 84.02% quarter-over-quarter. This erratic profitability raises serious questions about earnings quality and sustainability.
- Elevated Trailing Valuation Leaves No Room for Error: A trailing P/E of 96.26x, near the top of its recent historical range, prices in a perfect earnings recovery. Any disappointment in execution or margin normalization could trigger a severe valuation de-rating.
- Intensifying Competitive Threats: Recent FDA approval of Johnson & Johnson's oral psoriasis drug Icotyde introduces new competition for blockbuster Skyrizi. This threatens the growth trajectory of AbbVie's core immunology franchise.
- Leveraged Balance Sheet with Liquidity Strain: Negative shareholder equity (-21.12 Debt/Equity) and a current ratio of 0.67 indicate a highly leveraged capital structure and potential short-term liquidity pressure, despite strong overall cash flow.
ABBV Technical Analysis
The stock is in a sustained downtrend from its 52-week highs, with a 1-year price change of +17.29% but a 6-month decline of -4.38%, indicating recent weakness. Currently trading at $217.72, it sits approximately 49% above its 52-week low of $181.73 and 11% below its 52-week high of $244.81, positioning it in the lower-middle of its annual range, suggesting a potential value opportunity after a significant pullback. Recent momentum shows a short-term recovery, with a 1-month gain of +6.78% contrasting sharply with a 3-month loss of -6.19%, signaling a potential reversal or relief rally from oversold conditions, though this is underperforming the SPY's +6.31% 1-month gain. Key technical support is anchored at the 52-week low of $181.73, while resistance looms near the 52-week high of $244.81; a sustained breakout above resistance would signal a resumption of the long-term uptrend, while a breakdown below support could indicate deeper fundamental concerns. With a beta of 0.305, the stock exhibits significantly lower volatility than the broader market, which is unusual for a large-cap pharma and suggests it is viewed as a defensive holding, impacting potential risk-adjusted returns.
Beta
0.30
0.30x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$182-$245
Price range past year
Annual Return
+15.2%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +4.3% | +5.4% |
| 3m | -8.8% | +10.9% |
| 6m | -5.8% | +11.0% |
| 1y | +15.2% | +28.1% |
| ytd | -6.1% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue growth is robust but decelerating sequentially; Q4 2025 revenue was $16.62 billion, representing a 10.04% year-over-year increase, yet this follows a period of more volatile quarterly performance, including a Q3 2025 revenue of $15.78 billion. The growth is primarily driven by the immunology portfolio, with segment data showing Skyrizi at $5.01 billion, Rinvoq at $2.37 billion, and Humira at $1.25 billion, successfully offsetting the legacy drug's decline. The company is profitable but with significant quarterly volatility in margins; Q4 2025 net income was $1.82 billion with a net margin of 10.93%, and gross margin was exceptionally high at 84.02%, though this spiked from 66.38% in Q3, indicating potential one-time benefits or mix shifts rather than a sustainable trend. Profitability has improved from a net loss in Q4 2024, but the path is uneven, as seen in the low 1.18% net margin in Q3 2025, raising questions about earnings quality and sustainability. The balance sheet is leveraged with a debt-to-equity ratio of -21.12 (indicating negative shareholder equity due to large intangibles), but cash generation is strong with free cash flow TTM of $18.70 billion and an ROA of 10.03%. The substantial FCF, which supports the dividend (payout ratio of 2.76) and share repurchases, mitigates balance sheet concerns, though the negative current ratio of 0.67 points to potential short-term liquidity strain that is typical for the industry's financial structure.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given a positive net income of $1.82 billion in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 96.26x, while the forward P/E is substantially lower at 13.41x; this massive gap implies the market expects a significant earnings recovery and normalization in the coming year, pricing in the resolution of recent profitability volatility. Compared to the provided valuation data, AbbVie's trailing P/E of 96.26x is far above typical industry averages (implied by its own forward multiple), and its Price/Sales ratio of 6.65x and EV/Sales of 7.16x provide a more stable cross-check, suggesting the market is valuing the company on sales while awaiting margin stabilization. Historically, the stock's own trailing P/E has shown extreme swings, from 96.26x currently to as low as 13.47x in early 2023; trading near the top of this recent band indicates the market is currently pricing in a high degree of future earnings recovery, leaving little room for disappointment if execution falters.
PE
96.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -3572x~551x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's primary financial risk is the extreme volatility and questionable quality of its earnings, as evidenced by net margin swinging from 10.93% to 1.18% between consecutive quarters. This makes forecasting and valuation exceptionally difficult. The balance sheet is highly leveraged with negative shareholder equity (Debt/Equity of -21.12) and a weak current ratio of 0.67, indicating reliance on ongoing strong operating cash flow to service obligations. Revenue, while growing at 10.04% YoY, remains heavily concentrated in the immunology segment, creating dependency on Skyrizi and Rinvoq continuing to outpace competition.
Market & Competitive Risks: The stock trades at a trailing P/E of 96.26x, a premium valuation that leaves no room for execution missteps; any earnings disappointment could trigger severe multiple compression. Competitively, the recent FDA approval of J&J's oral psoriasis drug directly threatens Skyrizi's market share. Furthermore, the stock's low beta of 0.305, while defensive, also suggests it may not participate fully in market rallies, as seen in its significant underperformance versus the SPY across all measured periods (e.g., -15.08% over 6 months). Regulatory and political risks, such as drug pricing pressures and manufacturing issues (e.g., the recent FDA rejection for TrenibotE), add persistent overhangs.
Worst-Case Scenario: The worst-case scenario involves a combination of competitive setbacks for Skyrizi/Rinvoq, a failure of pipeline candidates like the obesity drug, and a sustained reversion of profit margins to the depressed Q3 2025 levels. This would cause forward EPS estimates to be cut dramatically, collapsing the forward P/E narrative and leading to a simultaneous de-rating of the trailing multiple. In this adverse scenario, the stock could realistically revisit its 52-week low of $181.73, representing a downside of approximately -17% from the current price of $217.72. A breach of that level could trigger a further decline toward the $170s, aligning with a max drawdown exceeding the recent -19.23%.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extreme earnings and margin volatility, as net margin swung from 1.18% to 10.93% in recent quarters, making the stock unpredictable. 2) Competitive Risk: New entrants like J&J's oral psoriasis drug threatening the growth of core asset Skyrizi. 3) Valuation Risk: The high trailing P/E of 96.26x leaves no room for error; any earnings disappointment could cause a sharp multiple contraction. 4) Balance Sheet Risk: High leverage (Debt/Equity of -21.12) and weak liquidity (Current Ratio 0.67), though mitigated by strong cash flow.
The 12-month forecast presents three scenarios. The base case (55% probability) sees the stock trading between $245 and $265, driven by steady immunology growth and margin stabilization, aligning with the consensus EPS estimate. The bull case (30% probability) targets $270 to $285 on accelerated growth and pipeline success. The bear case (15% probability) sees a decline to $181 to $210 if margins collapse and competition intensifies. The most likely outcome is the base case, predicated on the assumption that quarterly profitability becomes less volatile.
ABBV's valuation is bifurcated. On a trailing basis, it appears severely overvalued with a P/E of 96.26x, reflecting past earnings volatility. On a forward basis, it looks fairly valued or slightly undervalued with a P/E of 13.41x based on consensus EPS of $20.11. This forward multiple is reasonable for a large-cap pharma with 10% revenue growth. The market is currently paying a fair price for the company's expected earnings recovery in the coming year, but it is discounting significant uncertainty, as shown by the wide gap between trailing and forward multiples.
ABBV is a reasonable buy for income-focused, long-term investors who can tolerate quarterly earnings volatility. The forward P/E of 13.41x is attractive, and the 2.87% dividend yield is supported by massive $18.70B free cash flow. However, it is not a good buy for those seeking stable earnings or rapid growth, given the extreme margin swings and competitive threats. The ~24% implied upside to the base case target of ~$270 offers a favorable risk/reward, but the key risk is a 17% downside to the 52-week low if profitability disappoints.
ABBV is far more suitable for a long-term investment horizon of 3-5 years. Its low beta of 0.305 makes it a poor candidate for short-term trading, as it typically exhibits lower volatility and may not react sharply to market moves. The investment thesis revolves around the multi-year growth of its new drug franchises and the stability of its dividend, which requires time to play out. Given the quarterly earnings noise, short-term investors could be whipsawed. A minimum holding period of 18-24 months is suggested to allow for the earnings normalization story to materialize.